Samuel A. Funt

4.0k total citations · 1 hit paper
100 papers, 1.7k citations indexed

About

Samuel A. Funt is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Samuel A. Funt has authored 100 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Surgery, 45 papers in Oncology and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Samuel A. Funt's work include Bladder and Urothelial Cancer Treatments (47 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Testicular diseases and treatments (26 papers). Samuel A. Funt is often cited by papers focused on Bladder and Urothelial Cancer Treatments (47 papers), Cancer Immunotherapy and Biomarkers (30 papers) and Testicular diseases and treatments (26 papers). Samuel A. Funt collaborates with scholars based in United States, United Kingdom and Japan. Samuel A. Funt's co-authors include Jonathan E. Rosenberg, Dean F. Bajorin, Hikmat Al‐Ahmadie, Gopa Iyer, David B. Solit, Min Yuen Teo, Ashley Marie Regazzi, Alexandra Snyder, Irina Ostrovnaya and Jedd D. Wolchok and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Samuel A. Funt

90 papers receiving 1.7k citations

Hit Papers

Alterations in DNA Damage Response and Repair Genes as Po... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
    2018 374 citations Min Yuen Teo, Irina Ostrovnaya et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Samuel A. Funt United States 19 670 652 498 381 371 100 1.7k
Masahiko Watanabe Japan 22 716 1.1× 346 0.5× 450 0.9× 382 1.0× 205 0.6× 78 1.9k
Stefano Ferrero Italy 27 486 0.7× 535 0.8× 679 1.4× 213 0.6× 272 0.7× 121 2.3k
Xiaohua Jiang China 26 454 0.7× 525 0.8× 583 1.2× 649 1.7× 74 0.2× 78 1.8k
Marina Lesina Germany 16 1.2k 1.8× 616 0.9× 605 1.2× 149 0.4× 673 1.8× 25 2.1k
Anne F. Buckley United States 19 254 0.4× 159 0.2× 538 1.1× 231 0.6× 214 0.6× 52 1.5k
Hendrik Seeliger Germany 24 902 1.3× 567 0.9× 609 1.2× 508 1.3× 122 0.3× 64 1.8k
Helen Papadaki Greece 23 411 0.6× 311 0.5× 708 1.4× 222 0.6× 178 0.5× 78 1.9k
Fábio R. Faucz United States 28 300 0.4× 1.0k 1.6× 901 1.8× 419 1.1× 123 0.3× 141 2.7k
Joshua I. Warrick United States 22 239 0.4× 600 0.9× 592 1.2× 278 0.7× 115 0.3× 72 1.6k
Ying Xiong China 22 409 0.6× 322 0.5× 529 1.1× 331 0.9× 123 0.3× 92 1.5k

Countries citing papers authored by Samuel A. Funt

Since Specialization
Citations

This map shows the geographic impact of Samuel A. Funt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel A. Funt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel A. Funt more than expected).

Fields of papers citing papers by Samuel A. Funt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel A. Funt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel A. Funt. The network helps show where Samuel A. Funt may publish in the future.

Co-authorship network of co-authors of Samuel A. Funt

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel A. Funt. A scholar is included among the top collaborators of Samuel A. Funt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel A. Funt. Samuel A. Funt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Matulewicz, Richard S., Andrea Knežević, Brandon Williams, et al.. (2025). Comparison of serum and plasma microRNA expression levels in patients with germ cell tumours. British Journal of Urology. 135(5). 748–750.
2.
Shah, Rohan, Mario M. Leitão, Kevin A. Nguyen, et al.. (2024). Extramammary Paget disease. Part II. Evidence-based approach to management. Journal of the American Academy of Dermatology. 91(3). 421–430. 1 indexed citations
3.
Das, Jeeban Paul, Thomas Powles, Dean F. Bajorin, et al.. (2024). Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 42(16_suppl). 4581–4581. 1 indexed citations
4.
Funt, Samuel A., Petros Grivas, Xīn Gào, et al.. (2024). Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results.. Journal of Clinical Oncology. 42(16_suppl). 4575–4575. 1 indexed citations
5.
Guercio, Brendan J., Min Yuen Teo, Ashley Marie Regazzi, et al.. (2024). Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB).. Journal of Clinical Oncology. 42(16_suppl). 4571–4571. 1 indexed citations
6.
Knežević, Andrea, Sujata Patil, Joel Sheinfeld, et al.. (2024). Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease. Journal of Clinical Oncology. 42(26). 3130–3139. 4 indexed citations
7.
8.
Matulewicz, Richard S., Andrea Knežević, Joel Sheinfeld, et al.. (2024). Perioperative Serum MicroRNA 371a-3p and 372-3p Levels in Patients with Clinically Localized Testicular Masses. European Urology Open Science. 68. 1–9. 1 indexed citations
9.
Hoyt, Michael A., Jennifer S. Cheavens, Michael Daneshvar, et al.. (2023). Goal-Focused Emotion-Regulation Therapy (GET) in Young Adult Testicular Cancer Survivors: A Randomized Pilot Study. Annals of Behavioral Medicine. 57(9). 777–786. 6 indexed citations
10.
Vanguri, R., James W. Smithy, Yanyun Li, et al.. (2023). Integration of peripheral blood‐ and tissue‐based biomarkers of response to immune checkpoint blockade in urothelial carcinoma. The Journal of Pathology. 261(3). 349–360. 6 indexed citations
11.
Guercio, Brendan J., Min Yuen Teo, Ashley Marie Regazzi, et al.. (2023). Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB).. Journal of Clinical Oncology. 41(16_suppl). 4598–4598. 1 indexed citations
12.
Borch, Annie, Anne-Mette Bjerregaard, Oľga Østrup, et al.. (2023). Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy. Frontiers in Genetics. 14. 1058605–1058605.
13.
Truong, Hong, Vignesh Ravichandran, Yelena Kemel, et al.. (2022). Defining germline genetics of germ cell tumor: Implications for genetic testing and clinical management.. Journal of Clinical Oncology. 40(16_suppl). 5007–5007. 1 indexed citations
14.
Guercio, Brendan J., Eugene J. Pietzak, Samantha Brown, et al.. (2022). Neoadjuvant nivolumab (N) +/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 40(6_suppl). 498–498. 9 indexed citations
15.
Teo, Min Yuen, Hikmat Al‐Ahmadie, Kenneth Seier, et al.. (2021). Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. British Journal of Cancer. 124(7). 1214–1221. 21 indexed citations
16.
Feldman, Darren R., Nabil Adra, Mohammad Abu Zaid, et al.. (2021). Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors. Investigational New Drugs. 39(6). 1656–1663. 10 indexed citations
17.
Litchfield, Kevin, James L. Reading, Emilia L. Lim, et al.. (2020). Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. Nature Communications. 11(1). 3800–3800. 68 indexed citations
18.
Almassi, Nima, Eugene J. Pietzak, Samuel A. Funt, et al.. (2019). Characterization of actionable genetic alterations to guide targeted therapy for metastatic urothelial carcinoma.. Journal of Clinical Oncology. 37(7_suppl). 407–407. 1 indexed citations
19.
Dijk, Nick van, Samuel A. Funt, Christian U. Blank, et al.. (2018). The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. European Urology. 75(3). 435–444. 91 indexed citations
20.
Funt, Samuel A., et al.. (2009). A Right Atrial Mass, Patent Foramen Ovale, and Indwelling Central Venous Catheter in a Patient With a Malignancy: A Diagnostic and Therapeutic Dilemma. Journal of the American Society of Echocardiography. 23(4). 457.e1–457.e3. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masahiko Watanabe Breakdown of academic impact, for papers by Stefano Ferrero Breakdown of academic impact, for papers by Xiaohua Jiang Breakdown of academic impact, for papers by Marina Lesina Breakdown of academic impact, for papers by Anne F. Buckley Breakdown of academic impact, for papers by Hendrik Seeliger Breakdown of academic impact, for papers by Helen Papadaki Breakdown of academic impact, for papers by Fábio R. Faucz Breakdown of academic impact, for papers by Joshua I. Warrick Breakdown of academic impact, for papers by Ying Xiong
Rankless by CCL
2026